Interview with Edwin Harvey, Managing Director, Biogen Idec Argentina
Biogen Idec’s arrival in Argentina has been very recent. Could you explain to our readers why the time was right to take back your licences and to set up in…
Address: Av. del Libertador 350 – 7th Floor
1638 Vicente Lopez – Buenos Aires
Argentina
Tel: +54 11 5550 8150
Web: http://www.biogenidec.com/
Biogen Idec Argentina is part of a multinational company, headquartered in Cambridge, Massachusetts which has, since its formation, gained a commercial presence in over 29 markets. Their two leading products, AVONEX and RITUXAN, have for years ranked among the top ten biotechnology products sold globally.
Biogen Idec’s presence in Argentina provides therapeutic solutions through knowledge, research and support programs for the local multiple sclerosis. A great deal of commitment is shown to this new market as investment is flowing in the form of an R&D laboratory. This new venture in Latin America, and offices in Brazil and now Argentina, allows Biogen Idec to reach patients throughout the whole region.
Neurology
Biogen Idec’s arrival in Argentina has been very recent. Could you explain to our readers why the time was right to take back your licences and to set up in…
Has Argentina, for years one of the economic basket cases of Latin America, finally turned a corner? And is its pharma industry set for a bounce back? Firebrand TV…
Gustavo Pelizzari leads Elea, Argentina’s largest pharmaceutical company by sales volume, employing 1,350 people. Under his leadership, Elea has achieved the unique distinction of simultaneously leading both the retail pharmaceutical…
Gala Díaz Langou, a senior analyst and executive director at Argentina’s premier think tank CIPPEC, assesses the country’s recent transformative journey under President Milei. Drawing on 25 years of institutional…
Keila Barral, founder of Cromodata, brings together a personal journey of resilience and a career in technology to address one of Latin America’s biggest healthcare challenges: fragmented patient data. After…
Argentina’s pharmaceutical industry combines a robust domestic manufacturing base with growing international reach and regulatory credibility. In this interview, Mauricio Claverí, Chief Economist at CILFA, explores how local companies are…
Juan Jose Marconi, Executive Director of Cooperala, offers a unique perspective shaped by decades of leadership across Argentina’s pharmaceutical and healthcare sectors. With a strong academic background in applied mathematics,…
MSD’s Leonardo Semprun, writing in the June 2025 edition of DIA’s Global Forum magazine, reflects on some of the key lessons from the Latin America Town Hall at DIA Europe…
A roundup of some of the biggest stories coming out of Latin American pharma and healthcare, including Mexico’s move to speed up the drug review process; Sanfer’s acquisition of Columbia’s…
A roundup of top stories from Latin American pharma and healthcare, including the beginning of the Mexican government’s consolidated procurement of medicines; Libbs’ new biologics plant; Novo Nordisk’s USD 142.4…
An overview of some of the biggest news from Latin American pharma, including Onconic Therapeutics’ licensing deal with Laboratorios Sanfer for 19 LatAm countries; Lupin’s orphan drug partnership with Argentina’s…
A roundup of some of the latest stories coming out of Latin American pharma and healthcare, including Merck’s new distribution centre in Brazil; the region’s record dengue surge; Roemmers Laboratory’s…
Writing in the July 2023 edition of DIA’s Global Forum magazine, Mariana Abdala of Crystal Research outlines the vast room for improvement in Latin America’s clinical trial output, the region’s…
See our Cookie Privacy Policy Here
